Table 5 Univariate analysis for overall survival

Whole cohort

135

49

0.576

-

Age (years)

 < 52

66

18

0.669

0.011

 ≥ 52

69

31

0.478

Surgery type (n = 125)

 MRM

80

27

0.575

< 0.001

 BCS

39

9

0.734

 Palliative mastectomy

6

5

NA

Maximum tumor diameter (cm) (n = 125)

 < 4

65

14

0.740

< 0.001

 ≥ 4

60

27

0.445

pT stage (n = 125)

 Stages 1 & 2

70

14

0.741

< 0.001

 Stages 3 & 4

55

27

0.436

pN status (n = 119)

 Negative

68

13

0.735

0.001

 Positive

51

24

0.485

Capsular invasion (n = 51)

 Absent

17

6

0.676

0.186

 Present

34

18

0.403

LVI (n = 133)

 Absent

74

17

0.700

< 0.001

 Present

59

31

0.413

Grade

 II

22

6

0.693

0.279

 III

113

43

0.549

Initial TNM stage (n = 129)

 Stages I &II

71

0

0.718

< 0.001

 Stage III

47

21

0.508

 Stage IV

11

8

0.182

Pathological subtype

 Spindle cell carcinoma

10

6

0.281

0.036

 Others

125

43

0.600

Pathological subtype

 Squamous cell carcinoma

101

38

0.541

 Others

34

11

0.666

0.263

Ki-67% (n = 129)

 < 45

64

14

0.730

< 0.001

 ≥ 45

65

35

0.423

Molecular subtype

 TN

89

37

0.517

0.029

 Non-TN

46

12

0.697

NACT receipt

 Not received

81

21

0.601

0.027

 Received

41

18

0.513

NACT type (N = 41)

 Anthracycline & taxanes

27

9

0.577

0.268

 Others

14

9

0.408

Response to NACT (n = 40)

 RCB-0 & I

6

1

0.750

0.286

 RCB-II & III

34

16

0.487

ACT receipt

 Not received

40

17

0.480

0.019

 Received

80

20

0.699

ACT type (n = 80)

 Anthracycline

20

2

0.868

0.011

 Anthracycline & taxanes

40

9

0.686

 Others

20

9

0.533

ACT start (days) (n = 80)

 ≤ 30 days

41

9

0.739

0.716

 > 30 days

39

10

0.670

PORT (n = 119)

 No

25

10

0.578

0.253

 Yes

94

26

0.648